Healios K.K.
HLOSF
Get informed when a big investor buys or sells
+ FollowMarket Cap$40.77B
Close$
Share Statistics
| Market cap | $40.77 Billion |
|---|---|
| Enterprise Value | $34.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-20.59 |
| Beta | 1.43 |
| Outstanding Shares | 135,001,900 |
Return
| Return on Equity | 2.35% |
|---|---|
| Return on Assets | 0.89% |
| Return on Invested Capital | -15.16% |
Valuation & Multiples
| P/E Ratio | 60.89 |
|---|---|
| PEG | -39.16 |
| Price to Sales | - |
| Price to Book Ratio | 0.03 |
| Enterprise Value to Revenue | 580.75 |
| Enterprise Value to EBIT | -11.97 |
| Enterprise Value to Net Income | 166 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$108,632
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$270,003
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Healios K.K.
75 employees
CEO: Tadahisa S. Kagimoto Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key ...